Galapagos appoints Paul Stoffels as Chief Executive Officer
January 26 2022 - 4:01PM
- Succeeds current
Chief Executive Officer and co-founder
Onno van de Stolpe, following planned retirement
- Recognized as inspirational
industry leader with exceptional R&D as well as global
executive experience, and a strong focus on bringing innovative
medicines to patients
- Outstanding track record of
accelerated product development
in biotech and pharma through insightful acquisitions and strategic
partnerships
Mechelen, Belgium;
26 January
2022,
22.01 CET; regulated
information – Galapagos NV (Euronext & NASDAQ: GLPG)
is pleased to announce the appointment
of Dr. Paul
Stoffels as
Chief Executive Officer
(CEO), effective April 1,
2022. Dr.
Stoffels brings an
impressive track record of success in
innovative drug discovery
and development,
and a wealth of experience in biotech and
pharma, across a range of roles
and therapeutic areas.
“After a rigorous selection process, we are very
pleased to announce Paul as our next CEO. Given his extraordinary
R&D as well as managerial experience, extensive network, along
with his deep understanding of Galapagos’ strengths and potential,
we are convinced that Paul is uniquely qualified to lead
Galapagos,” said Dr. Raj Parekh, Chairman of Galapagos. “We want to
express our gratitude and deep appreciation to Onno, who founded
Galapagos in 1999 and tirelessly built out the company to become a
fully integrated European biotech with a differentiated pipeline
and a first product on the market.”
Onno van de Stolpe, retiring CEO and co-founder
of Galapagos, added: “My 23 years at the helm of this company
has been an incredible journey, and I could not be more honored to
hand over the baton to Paul. As a founder and board member in the
early years, Paul has a keen understanding of our roots as well as
who we are today. I strongly believe that Paul’s strategic
and inspirational leadership, along with his deep knowledge of
both the industry and Galapagos, make him the right next CEO to
deliver tremendous value to all stakeholders, including investors,
shareholders and patients.”
Dr. Paul Stoffels commented: “I was closely
involved in the foundation of Galapagos by Crucell and Tibotec in
1999 and have been following the company as it matured into the
fully-fledged biopharma that it is today. I am attracted by the
entrepreneurial culture and unwavering commitment to innovation at
Galapagos, its strong R&D capabilities, and growing commercial
footprint. Underpinned by strong financial resources and supported
by the long-term collaboration with Gilead, I am convinced of
Galapagos’ unique potential, and I am very excited and honored to
be appointed as CEO. I want to express my respect and appreciation
to Onno, who successfully built Galapagos from a start-up to an
independent, established publicly listed company. I am committed to
staying true to the company’s mission of bringing novel modes of
action medicines to patients in need of new treatment options.”
Previously, Paul was Vice Chairman of the
Executive Committee and Chief Scientific Officer of J&J, where
he spearheaded the Company’s research and product pipeline to set
the company wide innovation agenda, discovering and developing
transformational healthcare solutions, including the recent
development of a single-shot COVID-19 vaccine within a record time
frame. Prior to that, he was worldwide Chairman Pharmaceuticals of
J&J, which under his leadership significantly rejuvenated its
product pipeline and adopted a transformational R&D operating
model, resulting in the launch of 25 innovative medicines across
the globe. He joined J&J in 2002, with the acquisition of Virco
and Tibotec, where he was CEO and Chairman respectively, and led
the development of several breakthrough products for the treatment
of HIV. Galapagos was founded in 1999 as a joint venture
between Crucell and Tibotec, and Paul was member of the board of
directors of Galapagos from its foundation until 2002.
Paul studied Medicine at the University of
Diepenbeek and the University of Antwerp in Belgium and Infectious
Diseases and Tropical Medicine at the Institute of Tropical
Medicine in Antwerp, Belgium.
After a transition period during which Onno will
hand over his activities, Paul Stoffels* will fully take over as
CEO effective April 1, 2022.
About
GalapagosGalapagos NV discovers, develops, and
commercializes small molecule medicines with novel modes of action.
Our pipeline comprises discovery through Phase 3 programs in
inflammation, fibrosis, and other indications. Our ambition is to
become a leading global biopharmaceutical company focused on the
discovery, development, and commercialization of innovative
medicines. More information at www.glpg.com.
*Stoffels IMC BV, represented by Paul
Stoffels
This press release contains inside information
within the meaning of Regulation (EU) No 596/2014 of the European
Parliament and of the Council of 16 April 2014 on market abuse
(market abuse regulation).
ContactInvestors:Sofie
Van GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:Marieke VermeerschHead of Corporate
Communication +32 479 490 603
Evelyn FoxDirector Executive Communications+31 65 3591 999
communications@glpg.com
Forward-looking statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements regarding the
announced leadership transition and other statements contained in
this press release that are not historical facts and statements
identified by words such as “expects,” “anticipates,” “intends,”
and “plans,” or words of similar meaning. These forward-looking
statements are subject to risks, uncertainties and other factors
that could cause actual results to differ materially from those
referred to in the forward-looking statements and, therefore, the
reader should not place undue reliance on them. These risks,
uncertainties and other factors include, without limitation, the
risk that we may not be able to realize the expected benefits from
our planned leadership transition, that our leadership transition
may be disruptive to our business operations, and those risks and
uncertainties identified in our Annual Report on Form 20-F for the
year ended 31 December 2020 and our subsequent filings with the
SEC. The forward-looking statements contained herein are based on
management’s current expectations and beliefs and speak only as of
the date hereof, and Galapagos makes no commitment to update or
publicly release any revisions to forward-looking statements in
order to reflect new information or subsequent events,
circumstances or changes in expectations.
- Galapagos appoints Paul Stoffels as Chief Executive
Officer
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024